The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study

The aim of this study was to evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left ventricular (LV) and right ventricular (RV) function in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). LV and RV peak longitudinal and circumferential strain and strain rate (SR), which consisted of peak systolic SR (SRs), peak early diastolic SR (SRe), and peak atrial-diastolic SR (SRa) were analyzed using cardiac magnetic resonance imaging (CMRI) data from the recently published ATPAHSS-O trial (ambrisentan and tadalafil upfront combination therapy in SSc-PAH). Twenty-one patients completed the study protocol. Measures of RV systolic function (RV free wall [RVFW] peak longitudinal strain [pLS], RVFW peak longitudinal SRs [pLSRs]) and RV diastolic function (RVFW peak longitudinal SRa [pLSRa], RVFW peak circumferential SRe) were improved after treatment. LV systolic function (LV peak global longitudinal strain [pGLS]) and diastolic function (LV peak global longitudinal SRe [pGLSRe]) were also significantly improved at follow-up. Increased 6-min walk distance was significantly correlated with RVFW pLS and pLSRs, while the decrease in N-terminal pro-brain natriuretic peptide was correlated with LV pGLS. Increased cardiac index was associated with improved LV pGLSRe, and reduction in mean right atrial pressure was correlated with improved RVFW pLS and pLSRa. Combination therapy was associated with a significant improvement in both RV and LV function as assessed by CMR-derived strain and SR. Importantly, the improvement in RV and LV strain and SR correlated with improvements in known prognostic markers of PAH. (Approved by clinicaltrials.gov [NCT01042158] before patient recruitment.)

[1]  G. Pedrizzetti,et al.  Principles of cardiovascular magnetic resonance feature tracking and echocardiographic speckle tracking for informed clinical use , 2016, Journal of Cardiovascular Magnetic Resonance.

[2]  Maja Cikes,et al.  Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. , 2016, European heart journal.

[3]  P. Beerbaum,et al.  Cardiovascular Magnetic Resonance Myocardial Feature Tracking: Concepts and Clinical Applications , 2016, Circulation. Cardiovascular imaging.

[4]  T. Biering-Sørensen,et al.  Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction. , 2015, JACC. Cardiovascular imaging.

[5]  Stefan L. Zimmerman,et al.  Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[6]  M. Friedberg,et al.  Left Ventricular Myocardial Function in Children With Pulmonary Hypertension: Relation to Right Ventricular Performance and Hemodynamics. , 2015, Circulation. Cardiovascular imaging.

[7]  D. Bluemke,et al.  Left atrial structure and functional quantitation using cardiovascular magnetic resonance and multimodality tissue tracking: validation and reproducibility assessment , 2015, Journal of Cardiovascular Magnetic Resonance.

[8]  Stefan L. Zimmerman,et al.  Comparison of strain measurement from multimodality tissue tracking with strain-encoding MRI and harmonic phase MRI in pulmonary hypertension. , 2015, International Journal of Cardiology.

[9]  S. Solomon,et al.  Impact of lowering pulmonary vascular resistance on right and left ventricular deformation in pulmonary arterial hypertension , 2015, European journal of heart failure.

[10]  O. Sitbon,et al.  Treatment goals of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[11]  D. Bluemke,et al.  Multi-ethnic study of atherosclerosis: association between left atrial function using tissue tracking from cine MR imaging and myocardial fibrosis. , 2014, Radiology.

[12]  K. Okumura,et al.  Right Ventricular Diastolic Performance in Children With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Correlation of Echocardiographic Parameters With Invasive Reference Standards by High-Fidelity Micromanometer Catheter , 2014, Circulation. Cardiovascular imaging.

[13]  J. Lumens,et al.  Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. , 2013, Journal of the American College of Cardiology.

[14]  P. Pellikka,et al.  Outcome Prediction by Quantitative Right Ventricular Function Assessment in 575 Subjects Evaluated for Pulmonary Hypertension , 2013, Circulation. Cardiovascular imaging.

[15]  P. Pellikka,et al.  Impaired Left Ventricular Mechanics in Pulmonary Arterial Hypertension: Identification of a Cohort at High Risk , 2013, Circulation. Heart failure.

[16]  P. Pellikka,et al.  Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. , 2013, The American journal of cardiology.

[17]  N. Osman,et al.  The strain-encoded (SENC) MR imaging for detection of global right ventricular dysfunction in pulmonary hypertension , 2013, The International Journal of Cardiovascular Imaging.

[18]  R. Dweik,et al.  Prevalence and prognostic value of left ventricular diastolic dysfunction in idiopathic and heritable pulmonary arterial hypertension. , 2012, Chest.

[19]  N. Westerhof,et al.  Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. , 2012, Chest.

[20]  C. Spradley.  Tricuspid Annular Plane Systolic Excursion Is a Robust Outcome Measure in Systemic Sclerosis-associated Pulmonary Arterial Hypertension , 2012 .

[21]  D. MacIver.  The relative impact of circumferential and longitudinal shortening on left ventricular ejection fraction and stroke volume. , 2012, Experimental and clinical cardiology.

[22]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[23]  P. Pellikka,et al.  Right ventricular strain for prediction of survival in patients with pulmonary arterial hypertension. , 2011, Chest.

[24]  A. Zaiman,et al.  Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[25]  James D. Thomas,et al.  Ventricular Geometry, Strain, and Rotational Mechanics in Pulmonary Hypertension , 2010, Circulation.

[26]  B. Wiens,et al.  Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 , 2008, Circulation.

[27]  J. Foster,et al.  NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension , 2007, European Respiratory Journal.

[28]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[29]  T. Abraham,et al.  Tricuspid annular displacement predicts survival in pulmonary hypertension. , 2006, American journal of respiratory and critical care medicine.

[30]  William A Zoghbi,et al.  Evaluation of global and regional right ventricular systolic function in patients with pulmonary hypertension using a novel speckle tracking method. , 2006, The American journal of cardiology.

[31]  T. Marwick.  Measurement of strain and strain rate by echocardiography: ready for prime time? , 2006, Journal of the American College of Cardiology.

[32]  P. Wouters,et al.  Longitudinal but not circumferential deformation reflects global contractile function in the right ventricle with open pericardium. , 2006, American journal of physiology. Heart and circulatory physiology.

[33]  M. Pillinger,et al.  Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .

[34]  D. Kass,et al.  Sildenafil Inhibits β-Adrenergic–Stimulated Cardiac Contractility in Humans , 2005 .

[35]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[36]  D. Kass,et al.  Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. , 2005, Circulation.

[37]  T. Jones,et al.  Assessment of ventricular function and mass by cardiac magnetic resonance imaging , 2004, European Radiology.

[38]  James C Moon,et al.  Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. , 2004, American heart journal.

[39]  Harlan M Krumholz,et al.  The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. , 2003, Journal of the American College of Cardiology.

[40]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[41]  J L Cox,et al.  Significant left ventricular contribution to right ventricular systolic function. , 1991, The American journal of physiology.

[42]  R. F. Rushmer,et al.  The Functional Anatomy of Ventricular Contraction , 1953, Circulation research.